Syndax Pharmaceuticals, Inc.

Equities

SNDX

US87164F1057

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 01:30:00 17/07/2024 am IST			5-day change	1st Jan Change
24.81 ^USD	+1.76%		+9.92%	+14.81%

01/07	Syndax Pharmaceuticals, Inc.(NasdaqGS:SNDX) dropped from Russell 3000 Value Index	CI
01/07	Syndax Pharmaceuticals, Inc.(NasdaqGS:SNDX) dropped from Russell 2500 Value Index	CI

Syndax Pharmaceuticals, Inc. Appoints Lisa M. Coussens to its Scientific Advisory Board

January 31, 2017 at 05:30 pm IST

Syndax Pharmaceuticals, Inc. announced the appointment of Lisa M. Coussens, Ph.D., to its Scientific Advisory Board. Dr. Coussens currently serves as the Chair of the Department of Cell Developmental & Cancer Biology and Associate Director for Basic Research at the Knight Cancer Institute at the Oregon Health & Sciences University (OHSU).

Latest news about Syndax Pharmaceuticals, Inc.

Syndax Pharmaceuticals, Inc.(NasdaqGS:SNDX) dropped from Russell 3000 Value Index	01/07	CI
Syndax Pharmaceuticals, Inc.(NasdaqGS:SNDX) dropped from Russell 2500 Value Index	01/07	CI
Syndax Pharmaceuticals, Inc.(NasdaqGS:SNDX) dropped from Russell Small Cap Comp Value Index	01/07	CI
Syndax Pharmaceuticals, Inc.(NasdaqGS:SNDX) dropped from Russell 2000 Value Index	01/07	CI
Syndax Pharmaceuticals, Inc.(NasdaqGS:SNDX) dropped from Russell 3000E Value Index	01/07	CI
Jefferies Initiates Syndax Pharmaceuticals at Buy With $37 Price Target	28/06	MT
Stifel Raises Price Target on Syndax Pharmaceuticals to $42 From $40, Maintains Buy Rating	26/06	MT
Syndax Pharmaceuticals, Inc. Presents Updated Positive Data from BEAT AML and AUGMENT-102 Phase 1/2 Combination Trials of Revumenib in Patients with Acute Leukemias At EHA 2024 Congress	14/06	CI
Transcript : Syndax Pharmaceuticals, Inc. Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-12-2024 08:40 AM	12/06
Syndax Pharmaceuticals to Progress into Phase 1b Segment of Revumenib Trial	06/06	MT
Syndax Pharmaceuticals Announces Plans to Advance into Phase 1b Portion of Trial Evaluating Revumenib in Relapsed or Refractory Metastatic MSS CRC	06/06	CI
Transcript : Syndax Pharmaceuticals, Inc. Presents at Bank of America Health Care Conference 2024, May-16-2024 08:00 AM	16/05
Syndax Pharmaceuticals, Inc. Announces Board Changes	16/05	CI
Syndax Pharmaceuticals Q1 Net Loss Widens	08/05	MT
Transcript : Syndax Pharmaceuticals, Inc., Q1 2024 Earnings Call, May 08, 2024	08/05
Syndax Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	08/05	CI
Syndax Pharmaceuticals, Inc. Presents Positive Pediatric Data from Pivotal AUGMENT-101 Trial of Revumenib in Relapsed/Refractory KMT2Ar Acute Leukemia at ASPHO Plenary Session	08/04	CI
Syndax Pharmaceuticals, Inc. Announces Completion of Enrollment in AUGMENT-101 Pivotal Trial Cohort of Patients with Relapsed/Refractory mNPM1 Acute Myeloid Leukemia	28/03	CI
Syndax Pharmaceuticals Says FDA Grants Priority Review to New Drug Application for Acute Leukemia Treatment	27/03	MT
Syndax Says Revumenib NDA Granted FDA Priority Review	27/03	DJ
Syndax Announces FDA Priority Review of NDA for Revumenib for the Treatment of Relapsed/Refractory KMT2Ar Acute Leukemia	27/03	CI
JPMorgan Raises Price Target on Syndax Pharmaceuticals to $34 From $31, Maintains Overweight Rating	20/03	MT
Sector Update: Health Care Stocks Rise Monday Afternoon	18/03	MT
Syndax Pharmaceuticals Names Steven Closter Chief Commercial Officer	18/03	MT
Syndax Pharmaceuticals, Inc. Announces Executive Changes	18/03	CI

Chart Syndax Pharmaceuticals, Inc.

Duration

Period

More charts

Company Profile

Syndax Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. It is focused on developing pipeline of cancer therapies. Its product candidates include revumenib, and axatilimab. It is developing revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged also known as mixed lineage leukemia rearranged, acute leukemias including acute lymphoblastic leukemia and acute myeloid leukemia (AML), and necleophosmin 1, also known as NPM1, mutant A. It is also exploring the use of revumenib as a treatment in solid tumors, specifically its activity in metastatic colorectal cancer. It is also developing axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1 receptor (CSF-1R) in chronic graft-versus-host disease (cGVHD), as well as idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells.

Sector

Biotechnology & Medical Research

Calendar

05/08/2024 - Q2 2024 Earnings Release (Projected)

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

24.81 USD

Average target price

34.69 USD

Spread / Average Target

+39.83%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
SYNDAX PHARMACEUTICALS, INC.	+14.81%	210.85Cr
MODERNA, INC.	+25.83%	4.8TCr
LONZA GROUP AG	+45.94%	4.15TCr
IQVIA HOLDINGS INC.	+0.69%	4.24TCr
ALNYLAM PHARMACEUTICALS, INC.	+30.52%	3.16TCr
ICON PUBLIC LIMITED COMPANY	+22.30%	2.86TCr
CELLTRION, INC.	-6.35%	2.8TCr
UNITED THERAPEUTICS CORPORATION	+49.25%	1.46TCr
MEDPACE HOLDINGS, INC.	+49.18%	1.41TCr
BIO-TECHNE CORPORATION	+3.45%	1.26TCr

Other Biotechnology & Medical Research